Clinical Trials
8 trialsNCT00977574 2026-05-29
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03093155 2024-05-14
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
Phase 2 Completed
NCT00924066 2019-11-21
Ixabepilone to Treat Cervical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01168232 2019-08-08
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025155 2019-07-24
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00095979 2019-07-24
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00030706 2018-09-28
Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Montefiore Medical Center
Phase 2 Completed
NCT00070096 2013-06-24
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
National Cancer Institute (NCI)
Phase 2 Completed